Skip to main content

Taewoong Choi

Assistant Professor of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
DUMC Box 3961, Durham, NC 27710
2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710

Selected Grants

Long Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells

Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2021 - 2026

Fellowships, Gifts, and Supported Research

Prospective, Multicenter, Open-Label, Single Arm, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in Prevention of CAR-T associated Neurotoxicity in Subjects with Relapsed or Refractory DLBCL receiving Axicabtagene Ciloleucel (Yescarta┬«) · 2019 Principal Investigator · Jazz Pharmaceutical
KarMMa-3: a phase 3, multicenter, randomized, open-label study to compare the efficacy and safety of bb2121 versus standard triplet regimens in subjects with relapsed and refractory multiple myeloma · August 2019 Principal Investigator · Celgene

External Relationships

  • Janssen Pharmaceuticals

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.